Development of a cell-free split-luciferase biochemical assay as a tool for screening for inhibitors of challenging protein-protein interaction targets.

KRAS PI3K RAF luciferase protein-protein interaction screening

Journal

Wellcome open research
ISSN: 2398-502X
Titre abrégé: Wellcome Open Res
Pays: England
ID NLM: 101696457

Informations de publication

Date de publication:
2020
Historique:
accepted: 29 01 2020
entrez: 27 6 2020
pubmed: 27 6 2020
medline: 27 6 2020
Statut: epublish

Résumé

Targeting the interaction of proteins with weak binding affinities or low solubility represents a particular challenge for drug screening. The NanoLuc

Identifiants

pubmed: 32587898
doi: 10.12688/wellcomeopenres.15675.1
pmc: PMC7308888
doi:

Types de publication

Journal Article

Langues

eng

Pagination

20

Subventions

Organisme : Wellcome Trust
ID : 103799
Pays : United Kingdom
Organisme : Cancer Research UK
ID : FC001070
Pays : United Kingdom
Organisme : Medical Research Council
ID : FC001070
Pays : United Kingdom
Organisme : Wellcome Trust
ID : FC001070
Pays : United Kingdom

Informations de copyright

Copyright: © 2020 Cooley R et al.

Déclaration de conflit d'intérêts

Competing interests: Competing interests: B.F.B and K.V.W. are employees of Promega Corporation and J.T. is an employee of AstraZeneca. J.D. has acted as a consultant for AstraZeneca, Bayer, Novartis, Vividion and TheRas. None of the other authors of this manuscript have a financial interest related to this work.

Références

J Biomol Screen. 1999;4(2):67-73
pubmed: 10838414
Cell. 2000 Dec 8;103(6):931-43
pubmed: 11136978
Proc Natl Acad Sci U S A. 1994 Jun 21;91(13):5982-6
pubmed: 8016101
Cell. 2018 Jan 25;172(3):578-589.e17
pubmed: 29373830
Proc Natl Acad Sci U S A. 2019 Aug 6;116(32):15823-15829
pubmed: 31332011
Chem Biol. 2014 Sep 18;21(9):1162-70
pubmed: 25237860
Genes Dis. 2015 Mar;2(1):4-12
pubmed: 25815366
Nat Rev Cancer. 2018 Dec;18(12):767-777
pubmed: 30420765
Cell. 2013 May 23;153(5):1050-63
pubmed: 23706742
Cell. 2016 Apr 21;165(3):643-55
pubmed: 27104980
Drug Discov Today. 2002 Mar 15;7(6):353-63
pubmed: 11893544
Biochem J. 2019 Jan 31;476(2):365-374
pubmed: 30705085
J Biol Chem. 2019 Jun 21;294(25):9937-9948
pubmed: 31088913
J Med Chem. 2015 Mar 12;58(5):2265-74
pubmed: 25695162
Cancer Cell. 2013 Nov 11;24(5):617-30
pubmed: 24229709
Yao Xue Xue Bao. 2012 Sep;47(9):1159-63
pubmed: 23227545
J Biol Chem. 2007 Sep 7;282(36):26503-16
pubmed: 17635919
Curr Chem Genomics. 2009 May 28;3:22-32
pubmed: 20161833
Nat Rev Mol Cell Biol. 2003 May;4(5):373-84
pubmed: 12728271
Science. 2019 Mar 22;363(6433):1280-1281
pubmed: 30898918
Cell. 2007 Jun 1;129(5):957-68
pubmed: 17540175
ACS Chem Biol. 2016 Feb 19;11(2):400-8
pubmed: 26569370
Cell. 2017 Feb 23;168(5):878-889.e29
pubmed: 28235199
Cell. 2017 Jun 29;170(1):17-33
pubmed: 28666118
Cancer Cell. 2014 Mar 17;25(3):272-81
pubmed: 24651010

Auteurs

Rachel Cooley (R)

Francis Crick Institute, London, UK.

Neesha Kara (N)

Francis Crick Institute, London, UK.

Ning Sze Hui (NS)

Francis Crick Institute, London, UK.

Jonathan Tart (J)

AstraZeneca, Cambridge, UK.

Chloë Roustan (C)

Francis Crick Institute, London, UK.

Roger George (R)

Francis Crick Institute, London, UK.

David C Hancock (DC)

Francis Crick Institute, London, UK.

Brock F Binkowski (BF)

Promega, Madison, Wisconsin, USA.

Keith V Wood (KV)

Promega, Madison, Wisconsin, USA.

Mohamed Ismail (M)

Francis Crick Institute, London, UK.

Julian Downward (J)

Francis Crick Institute, London, UK.
Institute of Cancer Research, UK, London, UK.

Classifications MeSH